New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting
New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations. The agreement's completion will further enhance New Day Diagnostics' ability to improve lives by empowering people with innovative, accessible diagnostics.